Thursday, 5 November 2026European Markets

GLINTT And MELEXIS Have A High Dividend Yield And Return On Equity In The Technology Sector.

Loading stream...

(VIANEWS) - GLINTT (GLINT.LS) is among this list of stock assets with the highest dividend rate and return on equity on the Technology sector.

Financial Asset Price Forward Dividend Yield Return on Equity
GLINTT (GLINT.LS) €0.50 7.1% 6.67%
MELEXIS (MELE.BR) €73.35 4.92% 39.77%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. GLINTT (GLINT.LS)

7.1% Forward Dividend Yield and 6.67% Return On Equity

Glintt Global, S.A. provides IT consulting services for banking, insurance, public administration, and utilities sectors in Portugal, Spain, and Angola. It operates through two segments: Health and Other Markets. The company engages in the sale of equipment, furniture, consumables, and robotics solutions; development of architectural projects; and design and conception of lay-out and image for pharmacies, training, equipment maintenance, and consultancy projects. It licenses proprietary software solutions for healthcare providers, such as clinics, hospitals, pharmacies, and other bodies of the ministry of health; and develops, implements, and maintains software services for the health sector. In addition, the company implements ERPs, integrates internet systems, and develops tailor-made applications services. Further, the company develops, implements, and integrates partner platforms with emphasis on the BPM, ERP, BI and mobility solutions; and integrates IT infrastructures, as well as support for networking, security, storage systems, and database management. The company was formerly known as Glintt - Global Intelligent Technologies, S.A. and changed its name to Glintt Global, S.A. in July 2024. Glintt Global, S.A. was incorporated in 1995 and is based in Sintra, Portugal. Glintt Global, S.A. operates as a subsidiary of Farminveste - Investimentos, Participações E Gestão S.A.

Earnings Per Share

As for profitability, GLINTT has a trailing twelve months EPS of €0.05.

PE Ratio

GLINTT has a trailing twelve months price to earnings ratio of 9.92. Meaning, the purchaser of the share is investing €9.92 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.67%.

Moving Average

GLINTT's worth is higher than its 50-day moving average of €0.49 and way above its 200-day moving average of €0.42.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on Jun 25, 2024, the estimated forward annual dividend rate is 0.03 and the estimated forward annual dividend yield is 7.1%.

More news about GLINTT.

2. MELEXIS (MELE.BR)

4.92% Forward Dividend Yield and 39.77% Return On Equity

Melexis NV designs, develops, tests, and markets advanced integrated semiconductor devices primarily for the automotive industry in Europe, the Middle-East, Africa, the Asia Pacific, and North and Latin America. The company provides magnetic position, current, latch and switch, inductive position, speed, pressure, tire monitoring, temperature, and optical sensors ICs and time-of-flight; embedded motor, smart, fan and pump, smart LED, and pre-driver ICs; embedded lighting; and LIN transceiver, CAN transceiver, and RFID transceivers. The company was founded in 1988 and is headquartered in Ieper, Belgium. Melexis NV is a subsidiary of Xtrion N.V.

Earnings Per Share

As for profitability, MELEXIS has a trailing twelve months EPS of €5.17.

PE Ratio

MELEXIS has a trailing twelve months price to earnings ratio of 14.19. Meaning, the purchaser of the share is investing €14.19 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 39.77%.

More news about MELEXIS.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com